15t-(4-methoxy-phenyl)-pentadeca-2t,4t,6t,8t,10t,12t,14-heptaenoic acid | 102751-81-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 15t-(4-methoxy-phenyl)-pentadeca-2t,4t,6t,8t,10t,12t,14-heptaenoic acid
• 英文别名: 15t-(4-Methoxy-phenyl)-pentadeca-2t,4t,6t,8t,10t,12t,14-heptaensaeure
• CAS: 102751-81-5
• 化学式: C₂₂H₂₂O₃
• 分子量: 334.415
• InChiKey: MRBBFBVVROUYMX-GNYIYICCSA-N

反应信息

• 作为产物：
  描述：

  Dimethylcortisalin 在 氢氧化钾 作用下， 生成 15t-(4-methoxy-phenyl)-pentadeca-2t,4t,6t,8t,10t,12t,14-heptaenoic acid
  参考文献：
  名称：

  Gripenberg, Acta Chemica Scandinavica (1947), 1952, vol. 6, p. 580,586, 589

  摘要：

  DOI：

文献信息

• Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration
  作者：M. A. D. Tilanus、Willem Vaandrager、Marinus H. M. Cuypers、Adrianus M. Verbeek、Carel B. Hoyng

  DOI：10.1007/pl00007887

  日期：2000.6.20

  Background: A massive intraocular hemorrhage in the course of age-related macular degeneration (AMD) is a devastating event. We set out to determine the role of anticoagulant therapy prescribed for vascular or cardiac indications in the development of a massive hemorrhage.Methods: A retrospective case-controlled study was conducted of 50 cases of age-related macular degeneration complicated by massive subretinal and vitreous hemorrhage. The control group consisted of 50 cases of AMD with small subretinal hemorrhage. Results: There was a significant difference in the use of anticoagulant medication (warfarin sodium) between the groups. The difference in the use of antiplatelet medication (aspirin) between the groups was not significant. A patient with a massive intraocular hemorrhage and AMD is 11.6 times more likely to use anticoagulant medication. It appeared that more than 50% of the patients in the massive hemorrhage group were allowed to stop the anticoagulant medication.Conclusion: Anticoagulant medication poses a significant risk in the development of a massive intraocular hemorrhage in patients with exudative AMD. Antiplatelet medication poses a less significant risk. Physicians prescribing anticoagulant medication should be informed about the macular status of the patient. the In case of neovascular AMD, anticoagulant medication should be prescribed only for absolute systemic indications.